Symons Capital Management Inc. Has $4.83 Million Stock Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Symons Capital Management Inc. lessened its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 9.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 95,188 shares of the biopharmaceutical company’s stock after selling 9,524 shares during the quarter. Bristol-Myers Squibb comprises about 2.2% of Symons Capital Management Inc.’s investment portfolio, making the stock its 22nd largest position. Symons Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $4,827,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Garrett Wealth Advisory Group LLC acquired a new position in Bristol-Myers Squibb in the third quarter valued at about $26,000. Lenox Wealth Advisors LLC lifted its stake in Bristol-Myers Squibb by 555.7% in the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 539 shares during the period. Financial Gravity Wealth Inc. lifted its stake in Bristol-Myers Squibb by 101.2% in the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 327 shares during the period. 1 North Wealth Services LLC acquired a new position in Bristol-Myers Squibb in the third quarter valued at about $41,000. Finally, Endurance Wealth Management Inc. lifted its stake in Bristol-Myers Squibb by 119.6% in the second quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 500 shares during the period. 80.40% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE BMY traded up $0.44 during mid-day trading on Friday, reaching $58.02. 11,418,626 shares of the company’s stock were exchanged, compared to its average volume of 12,766,524. The firm has a market capitalization of $91.88 billion, a price-to-earnings ratio of 14.58, a PEG ratio of 1.31 and a beta of 0.71. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. The business has a fifty day simple moving average of $52.90 and a 200 day simple moving average of $48.19. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $58.46.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the Zacks’ consensus estimate of $1.06 by $0.11. The company had revenue of $6.01 billion for the quarter, compared to analyst estimates of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. Bristol-Myers Squibb’s revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the firm posted $1.09 earnings per share. Equities research analysts predict that Bristol-Myers Squibb Co will post 4.33 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a dividend of $0.41 per share. The ex-dividend date of this dividend was Thursday, October 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 2.83%. Bristol-Myers Squibb’s payout ratio is presently 41.21%.

Several equities analysts have weighed in on BMY shares. JPMorgan Chase & Co. set a $62.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, September 13th. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price on the stock in a research note on Wednesday, August 14th. Wolfe Research set a $66.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, November 1st. ValuEngine lowered Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research note on Friday, October 25th. Finally, UBS Group raised their price target on Bristol-Myers Squibb from $51.00 to $53.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $56.64.

In related news, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the transaction, the insider now directly owns 31,963 shares in the company, valued at $1,807,827.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP John E. Elicker sold 15,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares of the company’s stock, valued at $4,219,526.86. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by company insiders.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Further Reading: How does new data get added to a blockchain?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.